

VU Research Portal

Application of TLR agonists in cancer immunotherapy: from late to early, from systemic to local

Koster, B.D.

2020

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Koster, B. D. (2020). *Application of TLR agonists in cancer immunotherapy: from late to early, from systemic to local*.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

Table of contents

Chapter 1	General introduction and outline of this thesis <i>Curr. Opin. Oncol. 2015 Nov;27(6):482-8</i>	9
Chapter 2	Autologous tumor cell vaccination combined with systemic CpG-B and IFNα promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: A phase II trial <i>Cancer Immunol Immunother. 2019 Jun;68(6).</i>	27
Chapter 3	High and interrelated rates of PD-L1⁺CD14⁺ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancer <i>Cancer Immunol Res. 2015;3:48–58</i>	57
Chapter 4	Melanoma sequentially suppresses different DC subsets in the sentinel lymph node, affecting disease spread and recurrence <i>Cancer Immunol Res. 2017 Nov;5(11):969-977.</i>	87
Chapter 5	Response: Breslow thickness and excision interval affect the activation state of Langerhans cells in melanoma sentinel lymph nodes <i>Blood. 2012;119:4809–10.</i>	117
Chapter 6	T cell infiltration upon local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A⁺CD141⁺ cDC1 and CD14⁺ antigen-presenting cell recruitment <i>Manuscript in Preparation 2020.</i>	125
Chapter 7	Arming the melanoma sentinel lymph node through local administration of CpG-B and GM-CSF: recruitment and activation of BDCA3/ CD141⁺ dendritic cells and enhanced cross-presentation <i>Cancer Immunol Res. 2015;3:495–505.</i>	161

Chapter 8	Local adjuvant treatment with low-dose CpG-B offers durable protection against disease recurrence in clinical stage I–II melanoma: data from two randomized phase II trials	191
	<i>Clin Cancer Res. 2017;23:5679–86.</i>	
Chapter 9	In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma	215
	<i>Oncoimmunology. 2020;9:1708066.</i>	
Chapter 10	Summarizing discussion and future directions	231
	<i>Cancer Immunol Immunother. 2019;68:1681–8.</i>	
Appendices	Nederlandse Samenvatting	255
	Curriculum Vitae	261
	Dankwoord	263